🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  2. VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 small molecule active

    1 trial

  3. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  4. VCA-894A

    Vanda Pharmaceuticals Netherlands B.V.

    Charcot Marie Tooth Disease (CMT)

    phase 2 small molecule active

    1 trial

  5. VCAR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  6. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  7. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  8. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  9. VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Circadian Rhythm Sleep Disorders

    phase 2 small molecule completed

    1 trial

  10. VENETOCLAX, VENETOCLAX, SY-1425, VENETOCLAX, AZACITIDINE

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  11. VGX 3100

    INOVIO PHARMACEUTICALS, INC.

    Cervical Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  12. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Neoplasm

    phase 2 mab completed

    1 trial

  13. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

    phase 2 mab completed

    1 trial

  14. VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)

    Novartis Pharmaceuticals

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  15. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  16. VLY-686 (Tradipitant)

    Vanda Pharmaceuticals Netherlands B.V.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  17. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  18. VP-102 Cantharidin topical film forming solution

    Verrica Pharmaceuticals

    Common Wart

    phase 2 other completed

    1 trial

  19. VP-102 and applicator

    Verrica Pharmaceuticals

    Condylomata Acuminata

    phase 2 other completed

    1 trial

  20. VP-102 with applicator

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 2 other completed

    1 trial

  21. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Performance Anxiety

    phase 2 small molecule completed

    1 trial

  22. VSF-173

    Vanda Pharmaceuticals Netherlands B.V.

    Excessive Somnolence

    phase 2 small molecule completed

    1 trial

  23. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  24. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Dry Eye

    phase 2 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources